-------------------------------------------------------------------------------- DOCUMENT CONTROL (HEADER) -------------------------------------------------------------------------------- Document ID : DARX_STRAT_KB_PICHOLINE Title : Picholine Marocaine, Health Benefits, Study Quantities, Country Consumption, and Morocco Research Positioning Version : 1.1 Status : ACTIVE Classification : Internal, Not for Distribution Prepared By : Daralbeida Strategic Intelligence Reviewed By : (pending) Approved By : (pending) Approval Date : (pending) Owner : PYB / Daralbeida Date Created : May 2026 Last Revised : 2026-06-13 00:00 UTC Update Cycle : Upon receipt of Eurofins COA; upon publication of any new Picholine-specific study; upon any WHO or FDA guidance update Next Review Due : Upon receipt of first Eurofins COA Annual Review : Yes Retention : 3 years from date of creation Department : STRAT Style : BPGP Keywords : Picholine Marocaine, EVOO, polyphenols, PREDIMED, olive oil, Morocco, clinical research, consumption, FDA QHC, EFSA Related Docs : DARX_MI_KB_EVOO_HEALTH, DARX_SOP_SOURCING_001, DARX_AMZ_LISTING_001 Supersedes : DARX_STRAT_PICHOLINE_KB_20260501.txt Superseded By : (none, current version) -------------------------------------------------------------------------------- OUTLINE -------------------------------------------------------------------------------- 1. PURPOSE AND SCOPE 2. WHAT PICHOLINE MAROCAINE IS 3. POLYPHENOL CONTENT, WHAT THE SCIENCE SHOWS 4. HEALTH BENEFITS ATTRIBUTABLE TO PICHOLINE MAROCAINE 5. QUANTITIES USED IN CLINICAL STUDIES 6. RECOMMENDED DAILY INTAKE, REGULATORY AND SCIENTIFIC THRESHOLDS 7. PER CAPITA OLIVE OIL CONSUMPTION BY COUNTRY 8. THE CONSUMPTION GAP, WHAT IT MEANS COMMERCIALLY 9. MOROCCO'S ABSENCE FROM THE CLINICAL LITERATURE 10. HOW MOROCCO CAN ENTER THE EVIDENCE BASE 11. PHASED RESEARCH POSITIONING STRATEGY 12. COUNTRIES GROWING PICHOLINE, COMPETITIVE DYNAMICS 13. WHAT MOROCCO MUST DO BEFORE ANY OTHER COUNTRY DOES 14. AI PROMPTS 15. REVISION HISTORY 16. ACRONYMS 17. GLOSSARY DOCUMENT CONTROL (FOOTER) -------------------------------------------------------------------------------- ================================================================================ 1. PURPOSE AND SCOPE ================================================================================ This document addresses a specific strategic gap: Picholine Marocaine, the olive variety that represents 96% of Morocco's traditional olive grove area and is the source of Daralbeida's oil, has never been the subject of a human clinical intervention study with documented polyphenol content. The entire body of clinical evidence for EVOO health benefits has been built on Spanish, Italian, and Greek cultivars. This document consolidates what the science currently says about Picholine Marocaine, what quantities clinical studies have used, how consumption compares across countries, and how Morocco can strategically enter and influence the research record. ================================================================================ 2. WHAT PICHOLINE MAROCAINE IS ================================================================================ Picholine Marocaine is the dominant olive cultivar in Morocco. It covers more than 700,000 hectares and occupies 96% of the traditional olive grove area. It is a dual-aptitude variety, used for both table olives and oil extraction. The variety is known by several local names: Bousbina, Beldi, Bouchouika, Zitoun, Zit, and Soussia. It is closely related to Picholine de Languedoc (France), of which it is considered a clone, and shares likely kinship with the Algerian Sigoise variety. In California it is grown under the name Mission olive and studied by Agbiolab and UC Davis as a distinct California cultivar. The variety is highly resistant to drought and aridity, making it well adapted to Morocco's semi-arid growing conditions. It produces oil with high stability and excellent quality. The extraction process is more difficult than for most other cultivars, requiring longer beating times and specific mill adjustments, which increases processing cost but does not affect the final oil quality when managed correctly. Morocco's government confirms that 90% of national olive oil production comes from this cultivar. It is the most cultivated French variety when counted as Picholine de Languedoc, and it is grown in Israel, Chile, Uruguay, the United States, Italy, and Tunisia under various local names. ================================================================================ 3. POLYPHENOL CONTENT, WHAT THE SCIENCE SHOWS ================================================================================ The polyphenol content of Picholine Marocaine EVOO has been documented in several peer-reviewed laboratory studies and commercial COA records. The findings are as follows. Source / detail Polyphenol level and method ─────────────────────────────────────── ─────────────────────────────────── PMC 2020 monovarietal characterisation ~280 mg/kg; LC-MS study (standard commercial conditions) Agbiolab California (Mission = Equal to Picual and Coratina; LC-MS Picholine Marocaine) comparative analysis INRAE Morocco 2-year comparative study Upper tier among 13 cultivars; vs 12 varieties, identical conditions LC-MS Georgetown Olive Oil Co. commercial COA 530 mg/kg; Eurofins (Moroccan Picholine, retail product) Picholine de Languedoc published value Up to 700 mg/kg; Multiple (French clone of same cultivar) EU health claim minimum threshold 250 mg/kg; EFSA PREDIMED intervention oil threshold 480 mg/kg; Protocol The 280 mg/kg figure represents standard commercial conditions, average harvest timing, standard extraction, no optimisation for polyphenol preservation. The 530 mg/kg commercial COA and the 700 mg/kg Picholine de Languedoc figures represent early-harvest, cold-pressed, optimised production. The evidence is consistent: Picholine Marocaine sits in the high-polyphenol tier alongside Picual (Spain) and Coratina (Italy), the two cultivars with the highest documented polyphenol profiles in the clinical literature. It is not in the same tier as Arbequina, which is the dominant low-polyphenol commercial variety that accounts for most mass-market EVOO globally. ================================================================================ 4. HEALTH BENEFITS ATTRIBUTABLE TO PICHOLINE MAROCAINE ================================================================================ No human clinical study has directly tested Picholine Marocaine EVOO as the intervention product. This is the core gap. However, benefits can be attributed through two legitimate pathways. 4.1 PATHWAY 1, EVOO GENERIC ATTRIBUTION All benefits documented in the 28-study register apply to EVOO broadly. They apply to Picholine Marocaine oil insofar as that oil qualifies as EVOO and meets the polyphenol thresholds used in the relevant studies. At 480 mg/kg or above, which commercial Moroccan Picholine EVOO demonstrably reaches, the oil meets or exceeds the PREDIMED intervention threshold and can be positioned within that scientific framework. Health Outcome Risk Reduction Source Studies ─────────────────────────── ────────────────── ─────────────────────── Major cardiovascular events 8% to 30% PREDIMED, CORDIOPREV All-cause mortality 17% to 49% GISSI, Harvard, EPIC Stroke risk 11% to 83% Lyon, meta-analyses Cancer incidence 17% to 31% PLOS ONE meta 2022 Type 2 diabetes 16% to 40% PREDIMED, InterAct Dementia-related death 28% Harvard JAMA 2024 CVD mortality 12% to 19% Harvard JACC 2022 Body weight (inverse) ~9% difference Harvard pooled 2025 4.2 PATHWAY 2, VARIETY-SPECIFIC ATTRIBUTABLE BENEFITS One specific finding applies to Picholine Marocaine by structural derivation. The 2025 PREDIMED sub-analysis directly compared EVOO (with polyphenols) to common olive oil (without polyphenols) and found that common olive oil showed substantially weaker effects. This establishes that the protection is polyphenol-mediated. Since Picholine Marocaine produces high-polyphenol oil when properly harvested and extracted, it qualifies for the EVOO arm of that comparison, not the common olive oil arm. One additional Picholine-specific finding exists outside the clinical trial literature. OliveOil.com published that when compared with other varieties, Picholine olives may have a neuroprotective effect against Alzheimer's disease specifically due to their particularly high content of hydroxycinnamic acids, which reduce oxidative stress in neurodegenerative disorders. This is not a clinical trial finding but a biochemical attribution, it aligns with the Harvard dementia study result of 28% lower dementia-related death risk for high olive oil consumers. ================================================================================ 5. QUANTITIES USED IN CLINICAL STUDIES ================================================================================ Understanding the doses used in clinical studies is essential for three reasons: it establishes what a therapeutic intake looks like, it defines what volume a Daralbeida customer would need to consume to replicate study conditions, and it provides the basis for daily serving recommendations on product pages and marketing materials. Study Daily Dose Weekly Volume Format ─────────────────────── ──────────────── ─────────────── ─────────── PREDIMED (2013/2018) ~50 ml per day 1 litre/week Free supply CORDIOPREV (2022) ~40 ml per day ~280 ml/week Free supply Lyon Diet Heart (1999) Not isolated Part of Med. Diet advice diet pattern Harvard NHS/HPFS >7g per day ~50 ml/week Self-report (2022 JACC) (threshold) Harvard Dementia >7g per day ~50 ml/week Self-report (2024 JAMA) (threshold) EU health claim 20g per day 140 ml/week Label claim minimum (EFSA) minimum FDA QHC minimum ~28g per day ~200 ml/week Label claim (2 tbsp per day) (2 tablespoons) 5.1 KEY OBSERVATIONS ON QUANTITIES The PREDIMED dose of 1 litre per week (approximately 50 ml per day or about 3.5 tablespoons) is the most clinically significant threshold. It is the dose at which a 30% reduction in major cardiovascular events was demonstrated in a randomised controlled trial. This is higher than most consumers currently use. The Harvard cohort studies used a minimum threshold of greater than 7 grams per day (approximately half a tablespoon) to define the high-consumption group that showed mortality benefits. This is a much lower bar, achievable by anyone using olive oil as their primary cooking fat. The practical implication for Daralbeida is that even modest use of the product (half a tablespoon per day) places a consumer in the beneficial range for all-cause and CVD mortality outcomes per the Harvard evidence, while daily use at cooking quantities (3 tablespoons per day) approaches the PREDIMED therapeutic dose. A 500 ml bottle at the Harvard minimum dose (7g per day) lasts approximately 71 days. A 500 ml bottle at PREDIMED dose (50 ml per day) lasts 10 days. A 1 litre bottle at PREDIMED dose lasts 20 days. This volume math is relevant for repeat purchase frequency modelling and subscription pricing. ================================================================================ 6. RECOMMENDED DAILY INTAKE, REGULATORY AND SCIENTIFIC THRESHOLDS ================================================================================ Authority Threshold Basis Claimable ─────────────────── ────────────────────── ─────────────────── ────────── FDA (QHC 2004) 2 tbsp (~28g) per day CHD risk reduction Yes (US) EFSA (EU 2012) 20g per day Polyphenol Yes (EU) oxidative stress Harvard JACC 2022 7g per day minimum Mortality benefit Contextual PREDIMED protocol 50 ml per day CVD event Contextual reduction IOC recommendation 25-50 ml per day Mediterranean Reference diet pattern The FDA Qualified Health Claim (Docket 2003Q-0559) is the most immediately actionable regulatory instrument for Daralbeida. It permits the following hedged statement on US packaging and listings without any new study being required: Limited and not conclusive scientific evidence suggests that eating about 2 tablespoons of olive oil daily may reduce the risk of coronary heart disease. US trade counsel must confirm exact permitted language before use. ================================================================================ 7. PER CAPITA OLIVE OIL CONSUMPTION BY COUNTRY ================================================================================ Source: International Olive Council (IOC), 2022/23 crop year data. All figures in kilograms per person per year. Country Kg/Person/Year Role in Study Register ──────────────────── ──────────────── ────────────────────────────── Greece 9.3 Lead cohort studies (EPIC) Spain 7.5 PREDIMED, CORDIOPREV, SUN, EPIC Italy 7.4 GISSI, MICOL, GISSI-HF Morocco 4.0 No studies, origin country Portugal 3.7 No studies in register France 1.5 Lyon Diet Heart Study, 3C Study USA 1.1 Harvard NHS/HPFS, NIH-AARP Germany 0.9 Meta-analyses (DIfE) UK 0.8 InterAct Consortium Japan 0.4 Seven Countries Study Finland 0.3 Seven Countries Study China 0.1 Meta-analysis (lead author) Morocco consumes 4.0 kg per person per year, 3.6 times the US figure and above France, Germany, the UK, Japan, Finland, and China. It is the only country in the top five consumers by per capita intake that has produced no studies contributing to the clinical evidence base. This is the structural paradox: the country with the highest-polyphenol dominant cultivar, the fourth-highest per capita consumption among study-related countries, and 96% market penetration of a single high-performance variety has contributed zero primary research to the body of evidence that validates its product. ================================================================================ 8. THE CONSUMPTION GAP, WHAT IT MEANS COMMERCIALLY ================================================================================ Benchmark Kg/Year Daily Volume (ml) ──────────────────────────── ───────── ───────────────── PREDIMED therapeutic dose 7.8 50 Greece (lead per capita) 9.3 60 Morocco (origin country) 4.0 26 USA (Daralbeida target mkt) 1.1 7 The gap between current US consumption (1.1 kg/year) and the PREDIMED therapeutic dose (7.8 kg/year) is 6.7 kg per person per year. This represents a 7x growth multiple if any meaningful segment of the US population reaches the dose at which clinical benefits were demonstrated. At 335 million Americans, every 1% of the population reaching PREDIMED dose represents approximately 22,000 additional tonnes of annual EVOO demand. At Daralbeida's average retail price of $0.60 per ml, each 1% market penetration at therapeutic dose equates to approximately $13 billion in annual market value at the category level. The practical commercial opportunity for Daralbeida is not dependent on market penetration at therapeutic dose. It is dependent on acquiring consumers who are health-motivated, price-inelastic, and information-seeking, the segment that responds to documented polyphenol content and reads labels. That segment exists today without any new study being required. ================================================================================ 9. MOROCCO'S ABSENCE FROM THE CLINICAL LITERATURE ================================================================================ Of the 28 studies in the Daralbeida register, none were conducted in Morocco, none used Moroccan oil as the intervention product, and none cited Picholine Marocaine by name in a clinical context. This absence has three causes. 9.1 CAUSE 1, RESEARCH INFRASTRUCTURE Clinical nutrition trials require institutional ethics boards, clinical research organisations, participant recruitment infrastructure, and long-term funding commitments. Morocco's research infrastructure for human nutrition trials, while growing, has not historically been organised around olive oil as a specific research priority at the human intervention level. 9.2 CAUSE 2, INDUSTRY FRAGMENTATION Morocco's olive oil sector is dominated by small producers and traditional mills. The industry has not historically organised to co-fund or commission clinical research on its primary variety. The contrast with Spain is instructive: PREDIMED's EVOO was donated by industry (Hojiblanca and Patrimonio Comunal Olivarero), but the research framework was built by the Spanish research network over decades of public investment. 9.3 CAUSE 3, EXPORT-VOLUME ORIENTATION The majority of Moroccan olive oil exports have historically been sold in bulk to European bottlers who relabel it as Italian or Spanish. There was no commercial incentive for Moroccan producers to invest in variety-specific health research when the value was captured elsewhere. The shift toward branded Moroccan origin products, of which Daralbeida is an example, is what creates the commercial incentive for research investment. ================================================================================ 10. HOW MOROCCO CAN ENTER THE EVIDENCE BASE ================================================================================ There are four distinct entry points into the clinical literature, ordered by cost, timeline, and scientific weight. 10.1 ENTRY POINT 1, EUROFINS COA (IMMEDIATE, LOW COST) A Eurofins-accredited COA documenting polyphenol content in mg/kg for a specific Daralbeida lot is not a clinical study. It is, however, the prerequisite for all subsequent entries. Without a documented polyphenol number, no study can credibly position Moroccan Picholine EVOO within the PREDIMED framework. Cost: less than $500 per lot. Timeline: 4-6 weeks from sample submission. 10.2 ENTRY POINT 2, LABORATORY CHARACTERISATION PAPER (YEAR 1-2) A peer-reviewed laboratory paper benchmarking Picholine Marocaine EVOO from multiple Moroccan producers against the PREDIMED polyphenol threshold does not require human participants. It requires olive oil samples, LC-MS analysis, and a research partner with publishing capacity. Target journals: Food Chemistry, LWT, Food Science and Technology, Journal of Agricultural and Food Chemistry. Partner candidates: IAV Hassan II (Rabat), INRAE Morocco, Agbiolab California (which already has published Mission/Picholine Marocaine data). Cost: 15,000 to 40,000 USD. Scientific weight: establishes Picholine Marocaine formally in the polyphenol literature. 10.3 ENTRY POINT 3, HUMAN PILOT STUDY (YEAR 2-4) A 60-120 participant, 8-week randomised controlled pilot study using Daralbeida or Daralbeida-sourced Picholine Marocaine EVOO as the intervention product. Pre-registered on ClinicalTrials.gov. Primary outcome: plasma hydroxytyrosol and urinary polyphenol metabolites confirming bioavailability. Secondary outcomes: LDL oxidation, CRP, blood pressure. Partner candidates: Tufts Friedman School of Nutrition, UC Davis Olive Center, IAV Hassan II in consortium with a Spanish PREDIMED-network university. Cost: 300,000 to 600,000 USD. Scientific weight: first human evidence of Picholine Marocaine EVOO bioavailability, publishable in a tier 2 nutrition journal. 10.4 ENTRY POINT 4, LARGE RCT (YEAR 5-10) A 400-600 participant, 6-month randomised controlled trial with a documented Picholine Marocaine EVOO arm and a refined oil control arm. This is the design that produces causal evidence equivalent in structure to PREDIMED. Cost: 4 to 10 million USD. Funding pathway: IOC research grants, Moroccan Ministry of Agriculture under Generation Green 2020-2030, EU Neighbourhood Instrument grants, co-funding from Moroccan export-sector levy. Scientific weight: tier 1 journal publication, NEJM, Lancet, or JACC equivalent. ================================================================================ 11. PHASED RESEARCH POSITIONING STRATEGY ================================================================================ This section defines the recommended sequence of actions, their cost, and the milestone each produces for Daralbeida's commercial and scientific positioning. Phase / action Timeline / cost / output ────────────────────────────────── ────────────────────────────────────── 0 Eurofins COA, first lot Immediate; <500 USD; lot-specific polyphenol mg/kg 1 Eurofins COA, ongoing, every Each lot received; <500 USD/lot; shipment traceable COA record 2 Laboratory characterisation Year 1-2; 15K-40K USD; peer-reviewed paper, IAV Hassan II or polyphenol paper Agbiolab 3 Human pilot study Year 2-4; 300K-600K USD; first human evidence specific to Picholine Marocaine 4 Large RCT, multi-centre Year 5-10; 4M-10M USD; tier 1 journal, WHO dossier data 5 IOC dossier submission Year 7-9; staff cost; official IOC (Morocco as member state) recognition 6 WHO/FAO Codex dossier Year 8-12; legal cost; regulatory submission via CCNFSDU recognition Phase 0 and Phase 1 are entirely within Daralbeida's unilateral control today. Phases 2 through 6 require institutional partnerships, government alignment, or sector-level co-funding. The most urgent commercial priority is Phase 0. Everything else is contingent on that number existing. ================================================================================ 12. COUNTRIES GROWING PICHOLINE, COMPETITIVE DYNAMICS ================================================================================ Multiple countries grow Picholine-family olives and could theoretically claim credit for research on this cultivar. Understanding the competitive landscape is essential for Morocco to position its entry into the research record strategically. Country / local name and scale Research status ────────────────────────────────── ────────────────────────────────────── Morocco, Picholine Marocaine, No clinical studies; lab data only Beldi, Zitoun; 700,000 ha, 96% of area France, Picholine de Languedoc, AOC since 2004, INRAE lab research; Coiasse; dominant Fr. variety no human RCT USA (California), Mission olive; Agbiolab polyphenol comparative study; California only no human RCT Tunisia, Judoleine; minor No specific research Algeria, Sigoise (related); No specific research significant Israel, Picholine; minor No specific research Chile, Picholine; minor No specific research Italy, Picholine; very minor No specific research Morocco has the largest scale by a significant margin, 700,000 ha versus France's entire national olive sector of approximately 20,000 ha. France has the regulatory head start (AOC) and the research infrastructure advantage (INRAE). California has the Agbiolab data advantage. No country has yet produced a human clinical trial using Picholine-family oil as the documented intervention product. This gap is open to whoever moves first. France is the most likely rival to move first on a published Picholine polyphenol characterisation study given the INRAE infrastructure and the AOC commercial incentive. Morocco must be in the laboratory literature before France establishes the narrative that Picholine de Languedoc is the reference variety for health research, with Picholine Marocaine treated as a derivative. The naming priority matters. If the first high-impact paper says Picholine de Languedoc shows X benefit, all subsequent coverage reads France. If the first high-impact paper says Picholine Marocaine shows X benefit, all subsequent coverage reads Morocco. The science is identical. The attribution is determined by who publishes first. ================================================================================ 13. WHAT MOROCCO MUST DO BEFORE ANY OTHER COUNTRY DOES ================================================================================ The following actions constitute the minimum viable research positioning strategy for Morocco, and specifically for Daralbeida as the first Moroccan Picholine brand with a documented polyphenol record. 13.1 ACTION 1, OBTAIN THE EUROFINS COA ON THE FIRST SHIPMENT LOT This is non-negotiable and time-sensitive. Every lot shipped without a COA is a missed data point. The COA establishes the polyphenol baseline for Daralbeida's specific oil and opens every door that follows. 13.2 ACTION 2, CONTACT IAV HASSAN II FOR LABORATORY PARTNERSHIP Institut Agronomique et Veterinaire Hassan II in Rabat is Morocco's leading agricultural research institution. It has existing laboratory capacity for olive oil chemical analysis. A co-authored characterisation paper costs a fraction of a clinical trial and establishes Morocco's scientific presence in the Picholine polyphenol literature within 18 months. 13.3 ACTION 3, CONTACT INTERPROLIVE AND MOROCCO FOODEX Interprolive is Morocco's olive sector interprofessional body. Morocco Foodex (Director General: Ghita El Ghorfi) is the official export promotion agency. Both have mandates to support value-added Moroccan agricultural exports and both have access to sectoral levy funding that could co-finance a laboratory or pilot study. The argument to make: a peer-reviewed paper on Picholine Marocaine polyphenols benefits every Moroccan olive oil exporter, not just Daralbeida. 13.4 ACTION 4, FILE A PRE-REGISTRATION ON CLINICALTRIALS.GOV A ClinicalTrials.gov registration for a planned Picholine Marocaine EVOO human study, even if the study has not yet started, establishes Morocco's prior claim to the research space, signals seriousness to potential academic partners, and creates a citable entry in the international clinical trials registry. Registration cost: zero. Time required: hours. 13.5 ACTION 5, ENGAGE THE IOC OLIVE HEALTH INFORMATION SYSTEM OHIS is the International Olive Council's health evidence platform, managed jointly with the University of Navarra. Submitting Daralbeida's Eurofins COA data and any published laboratory characterisation paper to OHIS for inclusion in the weekly evidence digest begins building institutional recognition of Picholine Marocaine as a research-relevant variety within the IOC's own documentation. ================================================================================ 14. AI PROMPTS ================================================================================ This section provides reusable prompts for extending, refreshing, or operationalising the intelligence in this document. Copy a prompt between its delimiter rules and replace the editable tokens in [SQUARE_BRACKETS] before use. 14.1 PROMPT, REFRESH POLYPHENOL AND CONSUMPTION DATA ================================================================================ START OF PROMPT You are a research analyst for Daralbeida. Update the polyphenol content table in Section 3 and the per capita consumption table in Section 7 of the Picholine Marocaine knowledge base using sources no older than [CUTOFF_YEAR]. For each new figure, cite the source name, the measurement method, and the publication date. Flag any figure that conflicts with the existing value of [EXISTING_FIGURE] and explain the discrepancy. Preserve all existing figures that remain current and do not summarise away any data point. END OF PROMPT ================================================================================ 14.2 PROMPT, DRAFT PRODUCT-PAGE HEALTH COPY ================================================================================ START OF PROMPT Using only the dose and threshold data in Sections 5 and 6 of the Picholine Marocaine knowledge base, draft [NUMBER] short product-page paragraphs for the [MARKET] market. Stay within the FDA Qualified Health Claim hedged language for US copy. Reference the [DOSE_BASIS] threshold and the corresponding bottle duration math from Section 5. Do not state any claim that exceeds what the cited studies support, and append a note that US trade counsel must approve final language before publication. END OF PROMPT ================================================================================ ================================================================================ 15. REVISION HISTORY ================================================================================ Version Date Change ───────── ──────────── ────────────────────────────────────────────────── 1.0 May 2026 Original release as DAB-KB-PICH-001, prepared by Daralbeida Strategic Intelligence. 1.1 2026-06-13 Reformatted to BPGP v3.1: added header and footer control blocks, outline, AI Prompts, Revision History; tables converted to U+2500 separators; prose reflowed to single-line paragraphs. Content, figures, and citations preserved unchanged. ================================================================================ 16. ACRONYMS ================================================================================ AOC Appellation d'Origine Controlee (French protected origin designation) BPGP Business Plan / General Purpose (Daralbeida plain-text doc format) CCNFSDU Codex Committee on Nutrition and Foods for Special Dietary Uses CHD Coronary Heart Disease COA Certificate of Analysis CRP C-Reactive Protein (inflammatory marker) CVD Cardiovascular Disease EFSA European Food Safety Authority EU European Union EVOO Extra Virgin Olive Oil FAO Food and Agriculture Organization of the United Nations FDA Food and Drug Administration (United States) FFA Free Fatty Acidity HbA1c Glycated haemoglobin (Type 2 diabetes control marker) HR Hazard Ratio (relative risk in survival analysis) IAV Institut Agronomique et Veterinaire Hassan II (Rabat, Morocco) INRAE Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (France) IOC International Olive Council LC-MS Liquid Chromatography, Mass Spectrometry (polyphenol testing method) LDL Low-Density Lipoprotein (cholesterol fraction) Lp(a) Lipoprotein(a) (independent cardiovascular risk marker) LWT Lebensmittel-Wissenschaft und Technologie (Food Science and Technology, journal) NCD Non-Communicable Disease NEJM New England Journal of Medicine OHIS Olive Health Information System (IOC / University of Navarra) ONSSA Office National de Securite Sanitaire des produits Alimentaires OR Odds Ratio PREDIMED Prevencion con Dieta Mediterranea (Spanish multicenter RCT) QHC Qualified Health Claim (FDA regulatory instrument) RCT Randomised Controlled Trial RR Relative Risk STRAT Strategy (Daralbeida department code) T2D Type 2 Diabetes WHO World Health Organization ================================================================================ 17. GLOSSARY ================================================================================ Certificate Of Analysis Accredited laboratory report documenting the chemical composition and quality parameters of a specific olive oil lot. Required by FDA and used by Daralbeida for Gate 2 QC via Eurofins CAL. Abbreviated COA. Extra Virgin Olive Oil The highest IOC olive oil grade. Free fatty acidity 0.8% maximum, cold-extracted without chemical processing. Abbreviated EVOO. INRAE Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement. French national agricultural research institute. Referenced in Picholine Marocaine polyphenol comparative studies. Oleocanthal A phenolic compound in EVOO responsible for the characteristic throat-burning sensation. Demonstrated anti-inflammatory properties comparable to ibuprofen in vitro. Most commercially marketable EVOO bioactive. Oleuropein A secoiridoid polyphenol found in high concentrations in EVOO. Primary antioxidant compound. Associated with cardiovascular and anti-inflammatory benefits in the clinical literature. Picholine Marocaine The dominant olive cultivar in Morocco, covering 96% of traditional olive grove area. Also known as Bousbina, Beldi, Bouchouika, Zitoun, and Soussia. Related to Picholine de Languedoc and grown as Mission olive in California. Source of Daralbeida oil. Polyphenols Naturally occurring antioxidant compounds in EVOO. EU health claim minimum: 250 mg/kg (EFSA). PREDIMED intervention threshold: 480 mg/kg. Picholine Marocaine range: 280-700+ mg/kg. PREDIMED Prevencion con Dieta Mediterranea. Landmark Spanish clinical trial demonstrating cardiovascular benefits of EVOO-supplemented Mediterranean diet. Primary evidence base for EVOO health claims. -------------------------------------------------------------------------------- DOCUMENT CONTROL (FOOTER) -------------------------------------------------------------------------------- Document ID : DARX_STRAT_KB_PICHOLINE Version : 1.1 Status : ACTIVE Last Revised : 2026-06-13 00:00 UTC Update Cycle : Upon receipt of Eurofins COA; upon publication of any new Picholine-specific study; upon any WHO or FDA guidance update Next Review Due : Upon receipt of first Eurofins COA Annual Review : Yes Owner : PYB / Daralbeida Distribution : Internal only Review Triggers : Receipt of a Eurofins COA; publication of any Picholine-specific study; any WHO or FDA guidance update COMPLIANCE : Section 6 FDA QHC language must be reviewed by US trade counsel before use on any public-facing material. Section 11 phased cost estimates are indicative only and require formal quotation from partner institutions before commitment. This document is Internal, Not for Distribution; do not circulate externally without owner approval. Revision History: See Section 15 -------------------------------------------------------------------------------- END OF DOCUMENT --------------------------------------------------------------------------------